Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrocannabinol + iomazenil
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, and iomazenil, an iodine analog of the benzodiazepine receptor antagonist flumazenil. This combination has been studied in research settings to investigate how GABA deficits affect the psychotomimetic effects of THC. Research has shown that iomazenil enhances the psychosis-like effects of THC, suggesting an interaction between GABAergic and cannabinoid systems in the brain.
02
Targets
CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on tetrahydrocannabinol + iomazenil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrocannabinol + iomazenil.